Pre-order Enquiry
Request Free Sample
Healthcare
Aerospace & Defence
Agriculture
Automations
Chemicals & Advanced Materials
Food & Beverages
Information & Communication Technology
Oil & Gas
Power & EnergyDetailed TOC of MediPoint: Point of Care Diagnostics - Global Analysis and Market Forecasts
1 Table of Contents1 Table of Contents 8
1.1 List of Tables 12
1.2 List of Figures 16
2 Introduction 18
2.1 Catalyst 18
2.2 Related Reports 18
3 Industry Overview 19
3.1 POC Diagnostics Overview 19
3.2 Test Trends 21
3.2.1 Cardiac Markers POC Testing 21
3.2.2 Female Fertility and Pregnancy POC Testing 24
3.3 Mergers, Acquisitions, and Key Partnerships 29
4 Unmet Needs 33
4.1 Detection of Multiple Analytes 33
4.2 Sensitivity of Lateral Flow Technology 33
4.3 Analytical Quality 35
4.4 Markers for Myocardial Ischemia 35
4.5 Data Management 36
4.6 POC Diagnostics to Reduce Usage of Antibiotics 37
4.7 Cost-Effectiveness and Reimbursement 38
4.8 Gap between Physicians and Manufacturers 39
5 Market Drivers and Barriers 40
5.1 Drivers 40
5.1.1 Fast Turnaround Time 40
5.1.2 POC Molecular Testing Driving Infectious Disease POCT 40
5.1.3 Increasing Adoption of Cardiac Marker POCT 41
5.1.4 Expansion POC Testing Menu 42
5.1.5 Expansion of the Home-Testing Market 43
5.1.6 CLIA Waived Status for POCT 43
5.1.7 Rising Prevalence of Diseases 44
5.2 Barriers 44
5.2.1 Management of POCT 44
5.2.2 Competition with Laboratory Tests 45
5.2.3 Regulatory Compliance 46
5.2.4 Medical Device Excise Tax 47
6 Competitive Assessment 48
6.1 Company Share Analysis 48
6.1.1 Global 48
6.1.2 US 49
6.1.3 Europe 50
6.1.4 Asia-Pacific 51
6.2 Trends in Corporate Strategy 52
6.3 Major Players 53
6.3.1 Abbott Diagnostics 53
6.3.2 Akers Bioscience 56
6.3.3 Alere 59
6.3.4 Beckman Coulter 64
6.3.5 BioMerieux 66
6.3.6 Chembio Diagnostics 69
6.3.7 EKF Diagnostics 72
6.3.8 Meridian Bioscience 75
6.3.9 OraSure Technologies 79
6.3.10 Quidel 82
6.3.11 Radiometer Medical 86
6.3.12 Response Biomedical 89
6.3.13 Roche Diagnostics 93
6.3.14 Siemens Healthcare 97
6.3.15 Trinity Biotech 100
6.3.16 Other Companies 104
7 Pipeline Assessment 116
7.1 Overview 116
7.2 Pipeline Profiles 117
7.2.1 Cardiac Markers POCT 117
7.2.2 Female Fertility and Pregnancy POCT 118
7.2.3 Hematology POCT 118
7.2.4 Infectious Disease POCT 119
7.2.5 Immunochemistry POCT Analyzers 125
8 Market Outlook 126
8.1 By Market Segment 126
8.1.1 Global Overview 126
8.1.2 Cardiac Markers POCT 128
8.1.3 Female Fertility and Pregnancy POCT 130
8.1.4 Hematology POCT 132
8.1.5 Infectious Disease POCT 133
8.1.6 Immunochemistry POCT Analyzers 134
8.2 By Geography 136
8.2.1 Global Overview 136
8.2.2 US 139
8.2.3 France 141
8.2.4 Germany 144
8.2.5 Italy 146
8.2.6 Spain 150
8.2.7 UK 152
8.2.8 Japan 156
8.2.9 China 158
8.2.10 India 161
8.2.11 Brazil 164
9 Appendix 168
9.1 Bibliography 168
9.2 Abbreviations 172
9.3 Report Methodology 177
9.3.1 Overview 177
9.3.2 Coverage 177
9.3.3 Secondary Research 177
9.3.4 Forecasting Methodology 178
9.3.5 Primary Research — Key Opinion Leader Interviews 179
9.3.6 Primary Research - Physician and Industry Interviews 180
9.3.7 Expert Panel Validation 181
9.4 Physicians and Specialists Included in This Study 182
9.5 About the Authors 183
9.5.1 Analysts 183
9.5.2 Tyler Fletcher, Global Head of Medical Devices 184
9.6 About MediPoint 185
9.7 About GlobalData 185
9.8 Disclaimer 185
List of Figures, Tables and Charts Available in MediPoint: Point of Care Diagnostics - Global Analysis and Market Forecasts
1.1 List of TablesTable 1: Advantages and Disadvantages of POCT 20
Table 2: Global Troponin POCT Volume (thousands) Forecast by Country, 2012-2021 22
Table 3: Global B-type Natriuretic Peptide POCT Volume (thousands) Forecast by Country, 2012-2021 23
Table 4: Global Follicle-Stimulating Hormone POCT Volume Forecast by Country, 2012-2021 25
Table 5: Global Luteinizing Hormone POCT Volume (thousands) Forecast by Country, 2012-2021 27
Table 6: Global Human Chorionic Gonadotropin POCT Volume (thousands) Forecast by Country, 2012-2021 28
Table 7: Mergers, Acquisitions, and Key Partnerships, 2012-2016 30
Table 8: Company Profile - Abbott Diagnostics 54
Table 9: Abbott Diagnostics’ POC Portfolio Assessment, 2015 55
Table 10: SWOT Analysis - Abbott Diagnostics 56
Table 11: Company Profile - Akers Bioscience 57
Table 12: Aker Bioscience’s POC Portfolio Assessment, 2015 58
Table 13: SWOT Analysis - Akers Bioscience 58
Table 14: Company Profile - Alere 60
Table 15: Alere’s POC Portfolio Assessment, 2015 61
Table 16: SWOT Analysis - Alere 64
Table 17: Company Profile - Beckman Coulter 65
Table 18: Beckman Coulter’s POC Portfolio Assessment, 2015 65
Table 19: SWOT Analysis - Beckman Coulter 66
Table 20: Company Profile - BioMerieux 67
Table 21: BioMerieux’s POC Portfolio Assessment, 2015 68
Table 22: SWOT Analysis - BioMerieux 69
Table 23: Company Profile - Chembio Diagnostics 70
Table 24: Chembio Diagnostics’ POC Portfolio Assessment, 2015 71
Table 25: SWOT Analysis - Chembio Diagnostics 72
Table 26: Company Profile - EKF Diagnostics 73
Table 27: EKF Diagnostics’ POC Portfolio Assessment, 2015 74
Table 28: SWOT Analysis - EKF Diagnostics 75
Table 29: Company Profile - Meridian Bioscience 77
Table 30: Meridian Bioscience’s POC Portfolio Assessment, 2015 78
Table 31: SWOT Analysis - Meridian Bioscience 79
Table 32: Company Profile - OraSure Technologies 80
Table 33: OraSure Technologies’ POC Portfolio Assessment, 2015 81
Table 34: SWOT Analysis - OraSure Technologies 81
Table 35: Company Profile - Quidel 83
Table 36: Quidel’s POC Portfolio Assessment, 2015 84
Table 37: SWOT Analysis - Quidel 86
Table 38: Company Profile - Radiometer Medical 87
Table 39: Radiometer Medical’s POC Portfolio Assessment, 2015 88
Table 40: SWOT Analysis - Radiometer Medical 89
Table 41: Company Profile - Response Biomedical 91
Table 42: Response Biomedical’s POC Portfolio Assessment, 2015 92
Table 43: SWOT Analysis - Response Biomedical 93
Table 44: Company Profile - Roche Diagnostics 95
Table 45: Roche Diagnostics’ POC Portfolio Assessment, 2015 96
Table 46: SWOT Analysis - Roche Diagnostics 97
Table 47: Company Profile - Siemens Healthcare 98
Table 48: Siemens Healthcare’s POC Portfolio Assessment, 2015 99
Table 49: SWOT Analysis - Siemens Healthcare 100
Table 50: Company Profile - Trinity Biotech 101
Table 51: Trinity Biotech’s POC Portfolio Assessment, 2015 102
Table 52: SWOT Analysis - Trinity Biotech 103
Table 53: Other POC Companies in North America, 2015 104
Table 54: Other POC Companies in Europe, 2015 111
Table 55: Other POC Companies in APAC and Other Regions, 2015 114
Table 56: Key Cardiac Markers POCT Pipelines, 2015 117
Table 57: Key Female Fertility and Pregnancy POCT Pipelines, 2015 118
Table 58: Key Hematology POCT Pipelines, 2015 118
Table 59: Key Infectious Disease POCT Pipelines, 2015 119
Table 60: Key Immunochemistry POCT Analyzer Pipelines, 2015 125
Table 61: Global POC Diagnostics Sales Forecast ($m) by Market Segment, 2012-2021 127
Table 62: Cardiac Marker POCT Sales Forecast ($m), 2012-2021 130
Table 63: Fertility and Pregnancy POCT Sales Forecast ($m), 2012-2021 131
Table 64: Hematology POCT Sales Forecast ($m), 2012-2021 132
Table 65: Infectious Disease POCT Sales Forecast ($m), 2012-2021 134
Table 66: Immunochemistry POCT Analyzers Sales Forecast ($m), 2012-2021 135
Table 67: Global POC Diagnostics Sales Forecast ($m) by Country, 2012-2021 136
Table 68: US POC Diagnostics Sales Forecast ($m), 2012-2021 140
Table 69: France POC Diagnostics Sales Forecast ($m), 2012-2021 142
Table 70: Germany POC Diagnostics Sales Forecast ($m), 2012-2021 145
Table 71: Italy POC Diagnostics Sales Forecast ($m), 2012-2021 147
Table 72: Spain POC Diagnostics Sales Forecast ($m), 2012-2021 150
Table 73: UK POC Diagnostics Sales Forecast ($m), 2012-2021 153
Table 74: Japan POC Diagnostics Sales Forecast ($m), 2012-2021 156
Table 75: China POC Diagnostics Sales Forecast ($m), 2012-2021 160
Table 76: India POC Diagnostics Sales Forecast ($m), 2012-2021 162
Table 77: Brazil POC Diagnostics Sales Forecast ($m), 2012-2021 166
Table 78: POC Diagnostics - Primary Call Count by Country 180
1.2 List of Figures
Figure 1: Troponin POCT Volume by Country, 2012-2021 22
Figure 2: B-type Natriuretic Peptide POCT Volume by Country, 2012-2021 24
Figure 3: Follicle-Stimulating Hormone POCT Volume by Country, 2012-2021 26
Figure 4: Luteinizing Hormone POCT Volume by Country, 2012-2021 27
Figure 5: Human Chorionic Gonadotropin POCT Volume by Country, 2012-2021 29
Figure 6: Global POC Diagnostics Market, By Company Share, 2015 49
Figure 7: US POC Diagnostics Market, By Company Share, 2015 50
Figure 8: Europe POC Diagnostics Market, By Company Share, 2015 51
Figure 9: APAC POC Diagnostics Market, By Company Share, 2015 52
Figure 10: Global POC Diagnostics Sales Forecast ($m) by Market Segment, 2012-2021 127
Figure 11: Global POC Diagnostics Market Potential by Segment, 2021 128
Figure 12: Cardiac Marker POCT Sales Forecast ($m), 2012-2021 130
Figure 13: Fertility and Pregnancy POCT Sales Forecast ($m), 2012-2021 131
Figure 14: Hematology POCT Sales Forecast ($m), 2012-2021 133
Figure 15: Infectious Disease POCT Sales Forecast ($m), 2012-2021 134
Figure 16: Immunochemistry POCT Analyzers Sales Forecast ($m), 2012-2021 135
Figure 17: Global POC Diagnostics Sales Forecast ($m), 2012-2021 137
Figure 18: Global POC Diagnostics Market Share Forecast ($m) by Country, 2015 and 2021 138
Figure 19: Global POC Diagnostics Market Potential by Country, 2021 139
Figure 20: US POC Diagnostics Sales Forecast ($m), 2012-2021 140
Figure 21: US POC Diagnostics Market Revenue Breakdown, by Segment, 2015 141
Figure 22: France POC Diagnostics Sales Forecast ($m), 2012-2021 143
Figure 23: France POC Diagnostics Market Revenue Breakdown, by Segment, 2015 144
Figure 24: Germany POC Diagnostics Sales Forecast ($m), 2012-2021 145
Figure 25: Germany POC Diagnostics Market Revenue Breakdown, by Segment, 2015 146
Figure 26: Italy POC Diagnostics Sales Forecast ($m), 2012-2021 148
Figure 27: Italy POC Diagnostics Market Revenue Breakdown, by Segment, 2015 149
Figure 28: Spain POC Diagnostics Sales Forecast ($m), 2012-2021 151
Figure 29: Spain POC Diagnostics Market Revenue Breakdown, by Segment, 2015 152
Figure 30: UK POC Diagnostics Sales Forecast ($m), 2012-2021 154
Figure 31: UK POC Diagnostics Market Revenue Breakdown, by Segment, 2015 155
Figure 32: Japan POC Diagnostics Sales Forecast ($m), 2012-2021 157
Figure 33: Japan POC Diagnostics Market Revenue Breakdown, by Segment, 2015 158
Figure 34: China POC Diagnostics Sales Forecast ($m), 2012-2021 160
Figure 35: China POC Diagnostics Market Revenue Breakdown, by Segment, 2015 161
Figure 36: India POC Diagnostics Sales Forecast ($m), 2012-2021 163
Figure 37: India POC Diagnostics Market Revenue Breakdown, by Segment, 2015 164
Figure 38: Brazil POC Diagnostics Sales Forecast ($m), 2012-2021 166
Figure 39: Brazil POC Diagnostics Market Revenue Breakdown, by Segment, 2015 167
Figure 40: POC Diagnostics - Primary Call Count by Country (N=390) 180
Keyplayers in MediPoint: Point of Care Diagnostics - Global Analysis and Market Forecasts
Abbott DiagnosticsAkers Bioscience
Alere
Beckman Coulter
BioMerieux
Chembio Diagnostics
EKF Diagnostics
Meridian Bioscience
OraSure Technologies
Quidel
Radiometer Medical
Response Biomedical
Roche Diagnostics
Siemens Healthcare
Trinity Biotech
REQUEST TABLES & FIGURES MENTIONED IN THIS REPORT
